BPC-157: What the Published Research Covers

Research-use-only context. This article summarizes published third-party scientific literature and laboratory practice. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. US Prime Peptides products are supplied strictly for in vitro laboratory research and are not for human or veterinary use.

This article surveys what has actually been published about BPC-157, sorted by model system: cell culture, rodent, large-animal toxicology, and the small human record. It separates mechanistic findings from claims that are not established, and it states the compound's regulatory position in plain terms.

BPC-157 is a 15-residue fragment of a gastric juice protein

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a molecular formula of C62H98N16O22, and a molecular weight of about 1,419 daltons (PubChem CID 9941957). The sequence was reported by Sikiric and colleagues in a 1993 Journal of Physiology (Paris) paper as the active fragment of a larger protein, which they named "body protection compound" and described as a roughly 40-kilodalton component isolated from human gastric juice. The parent protein has not been characterized in the way a modern proteomics paper would require, and essentially all subsequent work has used the synthetic 15-mer.

The compound has carried several development codes. The Croatian company Pliva studied it as PL-10, PLD-116, and PL 14736, and the group's 2006 Inflammopharmacology paper refers to those programs as trials in inflammatory bowel disease. The same group coined the phrase "stable gastric pentadecapeptide," referring to reported resistance to acid and to gastric juice in vitro. Four prolines in the first eight residues give the chain a rigid, kinked backbone, and the absence of methionine, cysteine, or tryptophan means it lacks the residues most prone to oxidation.

BPC-157 is not an approved drug in the United States or anywhere else. The FDA's list of bulk substances nominated for compounding records that it was nominated and withdrawn, with the agency citing immunogenicity and impurity concerns and little or no safety data. The United States Anti-Doping Agency lists it under the World Anti-Doping Agency's category S0, non-approved substances. A research vial of BPC-157 is a laboratory chemical sold for in vitro work and documented by a certificate of analysis, not by a clinical record. The BPC-157 10 mg listing shows the lot-matched certificate format, and the Wolverine 10 mg / 10 mg blend listing shows how a two-component certificate reports each peptide separately.

Cell-culture findings: migration, survival, and receptor expression

The most mechanistically detailed in vitro work comes from a group at Chang Gung University in Taiwan. In a 2011 Journal of Applied Physiology paper, Chang and colleagues cultured explants of rat Achilles tendon and reported that BPC-157 accelerated the outgrowth of tendon fibroblasts from the explant. Isolated fibroblasts did not proliferate faster in the presence of the peptide by MTT assay, but they survived hydrogen peroxide stress better, migrated more in a transwell assay, and spread more quickly on culture dishes. The authors tied these effects to increased F-actin formation and to concentration-dependent phosphorylation of focal adhesion kinase and paxillin.

The same group followed up in Molecules in 2014 with a cDNA microarray on rat tendon fibroblasts and found growth hormone receptor among the most strongly up-regulated transcripts after exposure to BPC-157. The receptor increase was confirmed at the protein level, and adding growth hormone to those cells increased proliferation and activated Janus kinase 2. This is an in vitro observation in one rat cell type; it has not been shown in human cells or in a living organism.

Hsieh and colleagues reported in the Journal of Molecular Medicine in 2017 that BPC-157 increased tube formation by cultured human vascular endothelial cells and raised both mRNA and protein for vascular endothelial growth factor receptor 2, without changing VEGF-A itself. The peptide promoted internalization of the receptor and activated the VEGFR2-Akt-eNOS pathway; blocking endocytosis with dynasore abolished the effect. The paper also used the chick chorioallantoic membrane assay as an ex vivo vessel-density readout. Together these studies describe cytoskeletal and receptor-level responses in cultured cells, which is the strongest part of the BPC-157 literature.

Rodent models: the bulk of the published record

Most BPC-157 papers describe rodent experiments, and most of those come from a single group at the University of Zagreb. Cerovecki and colleagues, in a 2010 Journal of Orthopaedic Research paper, transected the medial collateral ligament in rats and reported improved functional, biomechanical, and histological scores over 90 days in animals that received the peptide by several routes. The Chang 2011 paper above complemented its cell work with a transected rat Achilles tendon model. Hsieh 2017 used laser Doppler scanning in a rat hind-limb ischemia model and reported faster recovery of blood flow and more vessels expressing VEGFR2 in the muscle.

The gastrointestinal literature is the oldest and largest. Sikiric and colleagues' 2011 review in Current Pharmaceutical Design collects rodent lesion models of the stomach, esophagus, duodenum, and colon, and the group's 2006 paper describes a rat model in which the stomach is distended and exposed to absolute alcohol, with BPC-157 reported to preserve vessel presentation at the serosal surface. A 2021 review in Frontiers in Pharmacology by Seiwerth and colleagues extends the same framework to skin wounds and fistulas in rats, and a 2022 Neural Regeneration Research review by Vukojevic and colleagues collects rodent central nervous system models.

Two features of this literature deserve emphasis. First, a large majority of the rodent studies share authors, so independent replication is thin; the 2025 narrative review by McGuire and colleagues in Current Reviews in Musculoskeletal Medicine and the 2025 literature and patent review by Józwiak and colleagues in Pharmaceuticals both make this point. Second, the proposed mechanisms, including the nitric oxide system, early growth response gene 1, and VEGFR2, are drawn from different models and have not been unified into a single receptor or pathway. No specific BPC-157 receptor has been identified.

Animal pharmacokinetics and toxicology

Two papers from a Chinese drug-development program fill in the preclinical safety and disposition picture. Xu and colleagues, in a 2020 Regulatory Toxicology and Pharmacology paper, reported single-exposure and repeated-exposure toxicity studies in mice, rats, rabbits, and dogs, along with local tolerance, genotoxicity, and embryo-fetal studies. They reported no test-article-related findings at the levels studied apart from a reversible decrease in creatinine in dogs at the highest level, and concluded that the data supported the start of a clinical study.

He and colleagues, in Frontiers in Pharmacology in 2022, reported the compound's pharmacokinetics in rats and beagle dogs. The elimination half-life of the intact peptide was under 30 minutes in both species, kinetics were linear across the levels tested, and tritium-labeled BPC-157 was rapidly broken into smaller peptide fragments and free amino acids that entered normal amino acid metabolism, with excretion through urine and bile. The short half-life is an important chemical fact for anyone designing an in vitro experiment: the intact 15-mer is not long-lived in the presence of peptidases, and assay medium containing serum will degrade it.

These are animal data generated under a drug-development program, and they describe the compound's behavior in those species only. They do not establish safety in humans, and they are not a property of any research vial.

The human record is small and uncontrolled

A 2026 systematic review by Poolton, Minett, and Kazmi in Acta Orthopaedica Belgica, registered with PROSPERO and searched to June 2026, found only three human studies of BPC-157 with a combined total of 30 participants: a retrospective series of 16 people with knee pain, a retrospective pilot of 12 people with interstitial cystitis, and a prospective pilot of two people. None had a control group, and the reviewers graded the certainty of evidence as very low. The Pliva inflammatory bowel disease program referenced in the Zagreb group's papers has no peer-reviewed efficacy publication that can be checked.

That is the entire controlled human evidence base: zero randomized trials. Every statement about what BPC-157 does in people is therefore an extrapolation from rodent or cell data. The Józwiak 2025 review notes that the compound has drawn attention precisely because it is widely sold online despite that gap, and the McGuire 2025 review frames the question in its title as "regeneration or risk."

What is established, what is not, and what a certificate shows

Established: the sequence and mass; reproducible cytoskeletal and migration responses in cultured rat tendon cells; VEGFR2 up-regulation in cultured human endothelial cells; faster recovery scores in several rat injury models; rapid proteolytic breakdown and a short half-life in rats and dogs; an unremarkable toxicology panel in four animal species at the levels tested. Not established: a receptor; a unified mechanism; independent replication of most rodent findings; any controlled human outcome; stability data for the peptide in culture medium; and anything about how a research lot behaves beyond what its certificate reports.

A research certificate for BPC-157 should show identity by mass spectrometry with an observed mass consistent with 1,419 daltons, purity by reverse-phase HPLC, net peptide content accounting for counter-ion and water, endotoxin by LAL, sterility, and heavy metals by ICP-MS, each tied to the lot number on the label and confirmed by an independent laboratory. Because the sequence is proline-rich, a chromatogram may show a small, reproducible conformer shoulder next to the main peak; that is a property of the molecule, not an impurity, and a well-written certificate will say so. For reading those lines see how to read a certificate of analysis; for the two-component case see reading a blend certificate; for the side-by-side with its most common blend partner see BPC-157 vs TB-500.

Frequently Asked Questions

What is BPC-157 made from?

BPC-157 is a synthetic 15-residue peptide whose sequence was reported in 1993 as a fragment of a larger protein found in human gastric juice. All published research uses the chemically synthesized peptide, not material isolated from the stomach, and the parent protein has never been fully characterized.

Is BPC-157 approved by the FDA?

No. BPC-157 is not an approved drug in the United States or any other country. The FDA's bulk-substances list records that it was nominated for compounding and withdrawn, citing a lack of safety data, and USADA lists it under WADA category S0 as a non-approved substance.

Has BPC-157 been studied in humans?

Barely. A 2026 systematic review found three uncontrolled human studies totaling 30 participants and no randomized trial, and graded the evidence as very low certainty. The published literature is overwhelmingly rodent and cell-culture work, much of it from a single research group.

What does BPC-157 do in cell culture?

In cultured rat tendon fibroblasts it increased cell migration, spreading, survival under oxidative stress, and growth hormone receptor expression; in cultured human endothelial cells it increased tube formation and VEGFR2 expression. These are in vitro findings from two groups and have not been generalized to other cell types.

Citations

1. Sikirić P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. PMID 8298609
2. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. PMID 17186181
3. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. PMID 21548867
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
5. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMID 25415472
6. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID 27847966
7. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. PMID 20225319
8. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID 34267654
9. Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMID 34380875
10. Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. PMID 32334036
11. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717
12. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. PMID 40005999
13. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID 40789979
14. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). PMID 42885452
15. PubChem. BPC-157, CID 9941957. National Library of Medicine. pubchem.ncbi.nlm.nih.gov
16. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
17. US Anti-Doping Agency. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide. usada.org

This article is for laboratory research reference only. US Prime Peptides products are supplied strictly for in vitro research. Not for human consumption.

Compliance Notice: US Prime Peptides products are supplied strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.